Regulus Therapeutics Inc. (NASDAQ:RGLS) – Equities researchers at Wedbush cut their Q1 2018 earnings estimates for shares of Regulus Therapeutics in a research note issued to investors on Monday, March 12th, according to Zacks Investment Research. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.12). Wedbush currently has a “Outperform” rating and a $4.00 target price on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2018 earnings at ($0.13) EPS, Q3 2018 earnings at ($0.13) EPS, Q4 2018 earnings at ($0.13) EPS, FY2018 earnings at ($0.51) EPS, FY2019 earnings at ($0.55) EPS, FY2020 earnings at ($0.64) EPS, FY2021 earnings at ($0.59) EPS and FY2022 earnings at ($0.14) EPS.
RGLS has been the subject of a number of other reports. B. Riley initiated coverage on shares of Regulus Therapeutics in a report on Wednesday, March 28th. They set a “neutral” rating and a $1.00 target price for the company. Zacks Investment Research cut shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 25th. Chardan Capital reissued a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Leerink Swann started coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective for the company. Finally, BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research note on Thursday, March 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $2.00.
RGLS stock traded down $0.04 during midday trading on Thursday, reaching $0.67. 185,325 shares of the company’s stock traded hands, compared to its average volume of 692,456. Regulus Therapeutics has a 52-week low of $0.63 and a 52-week high of $1.95. The stock has a market cap of $73.07, a P/E ratio of -0.70 and a beta of 1.69.
Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. Regulus Therapeutics had a negative net margin of 99,868.07% and a negative return on equity of 201.84%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million.
A number of hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its position in Regulus Therapeutics by 12.1% during the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares during the last quarter. Victory Capital Management Inc. lifted its position in Regulus Therapeutics by 18.2% during the fourth quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 50,530 shares during the last quarter. GSA Capital Partners LLP lifted its position in Regulus Therapeutics by 44.8% during the third quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 63,100 shares during the last quarter. Renaissance Technologies LLC lifted its position in Regulus Therapeutics by 215.7% during the fourth quarter. Renaissance Technologies LLC now owns 137,589 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 94,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Regulus Therapeutics by 189.1% during the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 240,890 shares during the last quarter. Institutional investors and hedge funds own 53.72% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Analysts Issue Forecasts for Regulus Therapeutics Inc.’s Q1 2018 Earnings (NASDAQ:RGLS)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/q1-2018-eps-estimates-for-regulus-therapeutics-inc-rgls-decreased-by-wedbush.html.
About Regulus Therapeutics
Regulus Therapeutics Inc, a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.
Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.